The Russian Direct Investment Fund (RDIF) announced that the phase II and III clinical trials of Russia developed COVID-19 vaccine have begun in India.
RDIF CEO, Kirill Dmitriev recently spoke about the efficacy rate of Sputnik V vaccine, displaying confidence in the numbers that they have achieved through data. Have a look at the interview here.
\
\
\
\
